DOCSLIB.ORG

Molecular Targeted Therapies for Indolent Lymphomas: Where Are

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molecular Targeted Therapies for Indolent Lymphomas: Where Are Hematology Meeting Reports 2009;3(3):4–9 SESSION I G. Saglio Molecular targeted therapies for indolent G. Parvis M. Bosa lymphomas: where are we? Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole, Orbassano, TO, Italy During the last decade the analysis11 suggested that mainte- development of new drugs for the nance therapy with rituximab, treatment of hematologic malig- either as four weekly infusions nancies has become really prom- every 6 months or as a single infu- ising. This innovative drug devel- sion every 2-3 months, should be opment is based on the translation added to standard therapy for into biochemical pharmacology patients with relapsed or refracto- of specific alterations of biologi- ry follicular lymphoma after suc- cal functions affecting tumour cessful induction therapy, to cells1. One of the most important improve progression-free and examples is imatinib: it showed overall survival. In contrast, pre- that it was possible to nullify the viously untreated patients seem pathognomic genetic lesion of not to acquire the same benefit chronic myelogenous leukemia from the maintenance treatment (CML). Drugs targeting unique (i.e. it prolongs the time to pro- disease-specific pathways have gression but does not prolong sur- also found potential applicability vival).12-13 in treating malignancies such as The data recently showed at CD20-positive non-Hodgkin’s 2008 ASH Meeting, coming from lymphoma (rituximab), follicular the clinical phase III studies lymphoma (Bcl-2-targeted named CLL8 and REACH, defi- agents2-6) and other B-cell neo- nitely support the employment of plasms (splenic tyrosine kinase rituximab in addition to chemo- [Syk] inhibitors;7-9 IkB kinase therapy (the standard regimen inhibitors10). being fludarabine plus cyclo- Rituximab, whose initial phosphamide) in patients affected employ in treatment of lym- by chronic lymphocytic leu- phomas dates to more than 10 kaemia, (the most common indo- years ago, is perhaps the most lent lymphoproliferative disorder) exploited and well-known “mol- both in first and in second line ecular-targeted” drug in treatment treatment, achieving superiority of indolent lymphoproliferative in terms of progression free sur- disorders. Its use in first-line ther- vival. apy of indolent CD20+ lym- Since rituximab is a chimeric phomas should not be discussed: antibody, there is a need to devel- nowadays, more concerns are op fully humanised antibodies, in about the most effective schedules order to minimise infusion reac- or combination regimens for tions and eliminate the develop- maintenance, above all in follicu- ment of human antibodies against lar lymphoma. A recent meta- the drug itself. In such a perspec- | 4 | 7th Meeting New Insights in Hematology, Venice, Italy, 26-29 April tive, new anti-CD20 antibodies named ofatu- al antibodies is offered by radioimmunothera- mumab,14 IMMU-106 (hA20),15 and GA10116 py (RIT), combining monoclonal antibodies have been developed and used in treatment of with radionuclides. Two different murine anti- recurrent lymphomas, with promising results CD20 antibodies (Y-90ibritumomab and 131I in phase I/II clinical studies. tositumomab) have been approved for the Further clinical evaluation of antibodies has treatment of rituximab-resistant, relapsed or been largely based on the knowledge of anti- refractory indolent lymphomas. Y-90ibritu- gen expression on the surface of lymphoma momab (Zevalin®) achieved higher ORR and cells and has led to the development of anti- CR rates than rituximab in relapsed/refractory bodies against many surface molecules: CD22 FL, but time to progression (TTP) and duration (unconjugated epratuzumab and calicheamicin of remission (DOR) were not statistically sig- conjugated CMC-544 [inotuzumab ozogam- nificant.22-23 131I tositumomab (Bexxar®) icin]), CD80 (galiximab), CD52 (alemtuzum- achieved ORR of 60-70% in heavily pretreated ab), CD23 (IDEC-152 [lumiliximab]) are the patients.24 Besides its use in treating refractory surface molecules against which monoclonal lymphomas, radioimmunotherapy also seems antibodies have been directed and employed in promising in consolidation approaches after clinical studies with patient affected by indo- chemoimmunotherapy, and it could represent a lent lymphomas and/or CLL. great chance to replace rituximab as mainte- Epratuzumab17 has induced responses in 24% nance treatment in indolent lymphomas. of patients with follicular lymphoma and in So far only in the context of experimental 15% of patients with recurrent diffuse large-B- studies, some murine and humanized forms of cell lymphoma, without dose-limiting toxic anti-CD22 antibodies have also been used con- effects. jugated with different radionuclides, among Galiximab18 achieved positive responses in which Y-90 is the most promising: this kind of 15% of patients affected by recurrent follicular CD22-RIT has been used in 16 patients with non-Hodgkin’s lymphoma, some of which previously treated NHL,25 obtaining an ORR of occurred as late as a year after treatment. 62% (75% in indolent NHL and 50% in Alemtuzumab19-20 has been approved by the aggressive NHL) with 25% CR/CRu rates. FDA for the treatment of chronic lymphocytic Three weekly infusions were feasible in this leukemia. About 30% of patients with CLL population with minimal toxicity. whose disease progressed after they received Among the best examples of target-therapies alkylating agents and fludarabine have had a in lymphomas, a place is occupied by immuno- response to alemtuzumab. When alemtuzumab toxins, consisting of protein toxins connected is used as the initial therapy in CLL, the to cell binding ligands including monoclonal response rate is about 80%. antibodies and growth factors, have been Lumiliximab21 showed he ability to induce developed for several decades to target hema- apoptosis of CLL cells in vitro; in a phase II tologic malignancies. Protein toxins from trial, CLL patients who received lumiliximab either plants or bacteria are extremely potent and FCR attained higher response rates (ORR based on their enzymatic inhibition of protein 71%, CR 48% and PR/PRu 23%) than histori- synthesis and induction of apoptosis. Plant cal FCR-only controls. A phase III trial com- toxins, particularly ricin, are useful for chemi- paring FCR with and without lumiliximab is cally conjugating to monoclonal antibodies, ongoing. and have shown clinical activity in several A chance to improve the effect of monoclon- types of lymphoma and leukemia; unfortunate- Hematology Meeting Reports 2009;3(3) | 5| G. Saglio et al. ly, their dose is generally limited by the possi- stantial clinical benefit.35 ble onset of vascular leak syndrome. In addition to proteasome inhibitors, the Denileukin diftitox26(the only approved drug immunomodulatory drugs (IMiDs), such as containing a protein toxin) has shown efficacy lenalidomide, have the potential to improve in cutaneous T-cell lymphoma, chronic lym- outcomes for patients with NHL. These drugs phocytic leukemia, and non-Hodgkin's lym- inhibit cell growth and proliferation by several phoma. Recombinant immunotoxin BL2227 is mechanisms, including blocking the effect of an anti-CD22 Fv fragment fused to truncated growth factors and stimulating T cells and nat- Pseudomonas exotoxin; it induces complete ural killer cells.36-37 Lenalidomide is particular- remissions in a high percentage of patients ly effective in lymphoproliferative disorders with chemoresistant hairy cell leukemia. such as multiple myeloma, and it is active in Proteasome inhibitors are an exciting class patients with various forms of NHL, with a of agents that have been used in multiple favourable side-effect profile. The most inter- myeloma and mantle cell lymphoma. esting results seem to be achieved if employed Proteasome inhibitors disrupt the pathways in mantle cell lymphoma, with a high response involved in the pathogenesis of non-Hodgkin’s rate reached even in patients with relapsed or lymphoma, and preclinical models showed refractory disease.38 Complimentary clinical sensitivity in lymphoma cell lines to protea- and pharmacological features suggest that some inhibitors.28-29 Bortezomib and carfil- lenalidomide may be effective when com- zomib are currently under study for indolent bined with monoclonal antibodies. Ongoing lymphomas.30-33 A 2006 study by de Vos and and future studies will provide further infor- colleagues compared weekly and twice-week- mation. ly schedules of bortezomib in combination During the past several decades, understand- with rituximab in a group of patients who were ing the many complex pathways of cell sur- sensitive to rituximab.34 Eighty-six percent of vival provided a fertile arena for formulating the patients had follicular lymphoma. new strategies to target these pathways in Toxicities differed between the two arms, with human cancer. It was demonstrated (1) the the twice-weekly arm experiencing more grade existence of pro- and anti-apoptotic relatives 3 adverse events (54% vs. 35%), but the out- of Bcl2 which, through specific interactions, comes were similar. However, without a ritux- modulate the balance of pro- and anti-apoptot- imab-alone arm, it is hard to determine the ic fates; (2) the existence of at least two dis- degree to which the bortezomib is contributing tinct pathways leading to apoptosis in mam- to these response rates. As there is not yet a malian cells, one involving the mitochondria good control population for the patients who (the intrinsic pathway) and other involving
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • B-Cell Targets to Treat Antibody-Mediated Rejection In
    Muro et al. Int J Transplant Res Med 2016, 2:023 Volume 2 | Issue 2 International Journal of Transplantation Research and Medicine Commentary: Open Access B-Cell Targets to Treat Antibody-Mediated Rejection in Transplantation Manuel Muro1*, Santiago Llorente2, Jose A Galian1, Francisco Boix1, Jorge Eguia1, Gema Gonzalez-Martinez1, Maria R Moya-Quiles1 and Alfredo Minguela1 1Immunology Service, University Clinic Hospital Virgen de la Arrixaca, Spain 2Nephrology Service, University Clinic Hospital Virgen de la Arrixaca, Spain *Corresponding author: Manuel Muro, PhD, Immunology Service, University Clinic Hospital “Virgen de la Arrixaca”, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain, Tel: 34-968-369599, E-mail: [email protected] Antibody-mediated rejection (AMR) in allograft transplantation APRIL (a proliferation-inducing ligand). These co-activation signals can be defined with a rapid increase in the levels of specific are required for B-cell differentiation into plasma cell and enhancing serological parameters after organ transplantation, presence of donor their posterior survival and are a key determinant of whether specific antibodies (DSAs) against human leukocyte antigen (HLA) developing B-cells will survive or die during the establishment molecules, blood group (ABO) antigens and/or endothelial cell of immuno-tolerance [5,6]. Important used agents commercially antigens (e.g. MICA, ECA, Vimentin, or ETAR) and also particular available are Tocilizumab (anti-IL6R) and Belimumab (BAFF). histological parameters [1,2]. If the AMR persists or progresses, the The receptors of BAFF and APRIL could also be important as treatment to eliminate the humoral component of acute rejection eventual targets, for example BAFF-R, TACI (transmembrane include three sequential steps: (a) steroid pulses, antibody removal activator and calcium modulator and cyclophyllin ligand interactor) (plasma exchange or immuno-adsorption) and high doses of and BCMA (B-cell maturation antigen).
    [Show full text]
  • Highlights from the Pan Pacific Lymphoma Conference
    October 2011 A SPECIAL MEETING REVIEW EDITION Volume 9, Issue 10, Supplement 24 Highlights From the Pan Pacific Lymphoma Conference August 15–19, 2011 Kauai, Hawaii Special Reporting on: • Aggressive T-Cell Lymphomas • Novel Agents With Activity in CLL/SLL • PTCL—Update on Novel Therapies • Agents Targeting the Stromal Elements of the Lymph Node • Inducing Apoptosis in Lymphoma Cells Through Novel Agents With Expert Commentary by: Bruce D. Cheson, MD Deputy Chief Division of Hematology-Oncology Head of Hematology Lombardi Comprehensive Cancer Center Georgetown University Hospital Washington, DC Eb: E W Th O N www.clinicaladvances.com ENGINEERING T H E N E X T GENERATION OF ANTIBODY-DRUG CONJUGATES 003203_sgncor_adcadvcaho_fa4.indd 2 8/25/11 11:13 AM An innovative approach to improving outcomes in patients with cancer Antibody-drug conjugates (ADCs) use a conditionally stable linker to combine the targeting specificity of monoclonal antibodies with the tumor-killing power of potent cytotoxic agents.1,2 This could allow potent drugs to be delivered directly to tumor cells with minimal systemic toxicity. Optimizing the parameters for clinical success Scientists at Seattle Genetics are focused on parameters critical to the effective performance of ADCs, including target antigen selection,3,4 linker stability5-7 and potent cytotoxic agents.4,7,8 Elements of an antibody-drug conjugate Linker ADCs link precision and Antibody attaches the cytotoxic agent to specific for a tumor-associated the antibody. Newer linker potency for greater activity
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
    Leukemia (2012) 26, 199–213 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu REVIEW Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma NWCJ van de Donk1, S Kamps1, T Mutis2 and HM Lokhorst1 1Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands and 2Department of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht, The Netherlands The introduction of autologous stem cell transplantation the myeloma patients achieved a partial response (PR) or stable combined with the introduction of immunomodulatory drugs disease following rituximab therapy. All these patients expressed (IMiDs) and proteasome inhibitors has significantly improved CD20 on their myeloma cells.2 However, as only B15–20% of survival of multiple myeloma patients. However, ultimately the majority of patients will develop refractory disease, indicating all myeloma patients express CD20 on their bone marrow the need for new treatment modalities. In preclinical and clinical plasma cells, new targets for immunotherapy need to be studies, promising results have been obtained with several identified. The search for other targets has led to the develop- monoclonal antibodies (mAbs) targeting the myeloma tumor ment of mAbs targeting growth factor receptors or adhesion cell or the bone marrow microenvironment. The mechanisms molecules on myeloma cells. Other newly developed mAbs underlying the therapeutic efficacy of these mAbs include are directed against cellular or non-cellular components of the direct induction of tumor cell apoptosis via inhibition or activation of target molecules, complement-dependent cyto- bone marrow microenvironment, resulting in the neutraliza- toxicity and antibody-dependent cell-mediated cytotoxicity tion of growth factors, inhibition of angiogenesis, modulation (ADCC).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer Et Al
    USOO8883146 B2 (12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer et al. (45) Date of Patent: *Nov. 11, 2014 (54) PROTEINFORMULATIONS AND METHODS (56) References Cited OF MAKING SAME U.S. PATENT DOCUMENTS (71) Applicant: AbbVie Inc., North Chicago, IL (US) 4,597,966 A 7/1986 Zolton et al. 4,877,608 A 10, 1989 Lee et al. (72) Inventors: Wolfgang Fraunhofer, Gurnee, IL (US); 5,237,054 A 8, 1993 Brinks et al. Annika Bartl, Ludwigshafen (DE); 5,608,038 A 3, 1997 Eiblet al. Hans-Juergen Krause, Biblis (DE); 5,702,699 A 12/1997 Hanish et al. Markus Tschoepe, Hessheim (DE); 6,090,382 A T/2000 Salfeld et al. Katharina Kaleta, Ludwigshafen (DE) 6,165.467 A 12/2000 Hagiwara et al. 6,171,586 B1 1/2001 Lam et al. 6,252,055 B1 6/2001 Relton (73) Assignee: AbbVie Inc., North Chicago, IL (US) 6,258,562 B1 7/2001 Salfeld et al. 6,281,336 B1 8/2001 Laursen et al. (*) Notice: Subject to any disclaimer, the term of this 6,436,397 B1 8/2002 Baker et al. patent is extended or adjusted under 35 6,485,932 B1 1 1/2002 McIntosh et al. U.S.C. 154(b) by 0 days. 6,509,015 B1 1/2003 Salfeld et al. 6,693,173 B2 2/2004 Mamidi et al. This patent is Subject to a terminal dis- 7,070,775 B2 7/2006 Le et al. claimer. 7,223,394 B2 5/2007 Salfeld et al.
    [Show full text]
  • Monoclonal Antibody Therapy for Classical Hodgkin Lymphoma
    Review: Clinical Trial Outcomes Monoclonal antibody therapy for classical Hodgkin lymphoma Clin. Invest. (2013) 3(9), 899–910 Major advances in the treatment of B-cell lymphoma resulting from the Ewa Paszkiewicz-Kozik & introduction of a monoclonal antibody to the CD20 antigen 15 years Jan Walewski* ago have left Hodgkin lymphoma (HL) aside. This has changed with the Department of Lymphoid Malignancies, The success of the anti-CD30 antibody conjugated with an antitubulin agent, Maria Sklodowska–Curie Memorial Institute & Oncology Centre, 5 Roentgen Street, 02–781 brentuximab vedotin, recently approved for the treatment of adult Warsaw, Poland + patients with relapsed or refractory CD30 HL following autologous stem *Author for correspondence: cell transplantation (ASCT) or following at least two prior therapies when Tel.: +48 22 546 3248 ASCT or for which multi-agent chemotherapy is not a treatment option. Fax: +48 22 546 3250 The magnitude of clinical activity of the new antibody has also prompted E-mail: [email protected] research on biologic functions of the CD30 molecule, as well as exploring other potential targets present on multinucleated Reed–Sternberg cells and the surrounding inflammatory area for a range of antibodies. This article will review the accumulating clinical data on the use of monoclonal antibodies in the treatment of classical HL with focus on CD20 and CD30 targets. We describe possible mechanisms of action, efficacy and toxicity related to administration of rituximab, brentuximab vedotin, daclizumab and other antibodies investigated in Phase I and II trials for classical HL. Keywords: brentuximab vedotin • CD20 • CD25 • CD30 • daclizumab • Hodgkin lymphoma • monoclonal antibodies • rituximab The treatment of B-cell lymphoid malignancies was revolutionized 15 years ago by the advent of the monoclonal antibody to the CD20 antigen.
    [Show full text]
  • Newer Monoclonal Antibodies for Hematological Malignancies
    Experimental Hematology 2008;36:755–768 Newer monoclonal antibodies for hematological malignancies Jorge Castillo, Eric Winer, and Peter Quesenberry Division of Hematology and Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, RI, USA (Received 28 March 2008; revised 28 April 2008; accepted 28 April 2008) Since the approval of rituximab in 1997, monoclonal antibodies have come to play an impor- tant role in the therapy of hematological malignancies. Rituximab, gemtuzumab ozogamicin, and alemtuzumab are US Food and Drug Administration–approved for treatment of B-cell lymphomas, acute myeloid leukemia, and chronic lymphocytic leukemia, respectively. Multi- ple monoclonal antibodies directed against new and not-so-new cellular antigens are undergo- ing development and investigation all over the world. Most of these new compounds have undergone primatization or humanization, improving their specificity and decreasing their antigenicity when compared to earlier murine or chimeric products. This review will focus on three major aspects of monoclonal antibody therapy: 1) new therapeutic approaches with currently approved agents; 2) preclinical and clinical experience accumulated on new agents in the last few years; discussion will include available phase I, II, and III data on ofa- tumumab, epratuzumab, CMC-544, HeFi-1, SGN-30, MDX-060, HuM195 (lintuzumab), galix- imab, lumiliximab, zanolimumab, and apolizumab; and 3) the role of naked and radiolabeled monoclonal antibodies in the hematopoietic stem cell transplantation setting. Ó 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. Since the discovery of hybridoma technology in 1975 [1], or chemotherapy (Table 2). Different strategies of action the production and variety of monoclonal antibodies have have been developed using monoclonal antibodies; these been exponentially increasing.
    [Show full text]